Predictores de rehospitalización en la esquizofrenia

Actas Espanolas de Psiquiatria

Volumn 25, Issue 4, 1997, Pages 217-224

  Figuerido, J L ^a,b   Gutierrez M ^a   Gonzalez Pinto A ^a   Ballesteros, J ^a   Perez De Heredia J L ^a   Ramirez F ^a   Elizagarate E ^a   Gonzalez Oliveros R ^a   Lopez P ^a  

^a Unidad de Enfermeria Urologica Hospital Santiago Apostol Miranda de Ebro Burgos Espana   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Epidemiology; Hospitalization; Negative Symptoms; Patient readmision; Positive Symptoms; Schizophrenia

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; MALE; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 3042902352     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Winokur G, Tsuang M. A clinical and familly history comparison of good outcome and poor outcome schizophrenia. Neuropsychobiology 1975;1:59-64.
2. Ribeiro SC, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF. Clinical predictors of 1 year outcome in schizophrenia. Psychopathology 1992;25:331-4.
3. Harding CM, Zubin J, Strauss J. Chronicity in Schizophrenia: Revisited. Br J Psychiatry 1992;161(Suppl 18):27-37.
4. Jonhson H, Nyman F. Predicting log-term outcome in schizophrenia. Acta Psychiat Scand 1991;83:342-6.
5. De Dios Francos A, Goñi Labat AI, Medina Fernández MA, De la Gándara Martín JJ. Factores pronóticos en pacientes esquizofrénicos. Actas Luso-Esp Neurol Psiquiatr 1994;22(3):121-5.
6. Wilcox JA. Thought disorder and relapse in schizophrenia. Psychopatology 1990;23:153-6.
7. Peralta V, Cuesta MJ. El valor pronóstico de los trastornos del pensamiento en esquizofrenia. Actas Luso-Esp Neurol Psiquiatr 1991;19(1)23-9.
8. Pogue Geile MF, Harrow M. Negative and positive symptoms in schizophrenia and depresion: A follow up. Schizophr Bull 1984;10:371-87.
9. Andreasen N, Flaum M, Swaize VW, Tyrell G, Ardnt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry 1990;47: 615-21.
10. Biehl H, Maurer K, Schubart C, Krumm B, Jung E. Prediction of outcome and utilization of medical services in a prospective study of first onset schizophrenics: Results of a five year follow up study. Eur Arch Psychiatry Neurol Sci 1986;236:139-47.
11. Kay SR, Opler LA. The positive-negative dimension in schizophrenia. Its validity and significance. Psychiatr Develop 1987;2:79-103.
12. Falloon IR. Expresed emotions: Current controversies. Psychol Med 1988;18:269-74.
13. Mac Millan JF, Gold A, Crow TJ. Expresed emotion and relapse. Br J Psychiatry 1986;148:133-43.
14. Soni SD, Brownlee M. Alcohol abuse in chronic schizophrenics: simplications for management in the community. Acta Psychiatr Scand 1991;84:272-6.
15. Caton CL, Koh SP, Fleiss JL. Rehospitalization in chronic schizophrenia. J Nerv Ment Dis 1985;173: 139-48.
16. Kissling W. Guidelines for neuroleptic relapse prevention in schizophrenia: proceedings of a consensus conference held april 19-20 1989. Bruges. (Belgium). Springer Verlag 1991.
17. Carpenter WT, Heinrichs DW, Wagnan AM. Deficit and nondeficit forms of schizofrenia: The concept. Am J Psychiatry 1988;145:578-83.
18. Angst J. European Long term follow up studies of schizophrenia. Schizophr Bull 1988;14:501-13.
19. Mc Glashan TH. A selective review of recent North American long-term follow up studies of schizophrenia. Schizophr Bull 1988;14:515-42.
20. Spitzer MD, Williams JB. Structured Clinical Interview for DSM III-R. Patient Version (SCIP-P). Nueva York, 1985.
21. Opler LA, Kay SR, Lindenmayer JP, Fiszbein A. Structured clinical interview for the positive and negative syndrome scale. SCI-PANSS. Toronto: Multi-Health systems, 1992.
22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
23. Peralta Martín V, Cuesta Zorita MJ. Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso-Esp Neurol Psiquiatr 1994;22(4):171-7.
24. National Institute of Mental Health. CGI (clinical global impresions). Manual for the ECDEU assesment battery 2 rev. En Guy W, Bonato RR, editores. Chavy Chase. Maryland, 1979.
25. Norusis MJ. SPSS/PC+v20. Base manual. Spss Inc. Chicago, 1988.
26. Lee ET. Stadistical methods for survival data analysis. New York: John Wiley, 1992.
27. Gutiérrez M, Aldama E, González Pinto A, Elizagarate E, Artamendi M, Figuerido Poulain JL. Neurolépticos atípicos, Depot y nuevos neurolépticos en el tratamiento de la esquizofrenia. En Gutiérrez M, Ezcurra J, Pichot P, editores. Avances en Psicofarmacología. Barcelona: Ediciones en Neurociencias, 1994:239-51.
28. Kaplan HI, Sadock BJ. Tratado de Psiquiatría. Barcelona: Salvat, 1989.
29. Biehl H, Maurer K, Schubart C, Krumm B, Jung E. Prediction of outcome and utilization of medical services in a prospective study of first onset schizophrenics: Results of a five year follow up study. Eur Arch Psychiatry Neurol Sci 1986;236:139-47.
30. Malla AK, Norman RM, Williamson P, Cortese L, Díaz F. Three syndrome concept of schizophrenia. A factor analytic study. Schizophr Res 1993;10:143-50.
31. Guimón J, Ylla L. Limitaciones del diagnóstico según el modelo biológico. En Guimón, Mezzich, Berrios. Diagnostico en psiquiatría. Barcelona: Salvat, 1988.
32. Cuevas C, González Rivera JL. Cumplimiento con la medicación neuroléptica y curso de la esquizofrenia. Psiquis 1994;15(3):21.
33. Carone BJ, Harrow M, Westermeyer JF. Posthospital course and outcome in schizophrenia. Arch Gen Psychiatry 1991;48(3):247-53.
34. González Torres MA, Eguiluz JI, Galletero JM, Mendivil J. Tratamiento hospitalario de la esquizofrenia. En Gutiérrez M, Ezcurra J, Pichot J, editores. Esquizofrenia entre la sociogénesis y el condicionamiento biológico II. Tomo II. Barcelona: Ediciones en Neurociencias, 1995:145-63.
35. Mc Kay AVP, Crow TJ. Positive and negative Schizophrenic symptoms and the role of dopamine. Br J Psychiary 1980;137:379-86.
36. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health. Longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-46.
37. Lindenmayer JP, Kay SR, Friedman C. Negative and positive schizophrenic syndromes after the acute phase: A prospective follow up. Compreh Psychiatr 1986;27(4):276-86.
38. Kay SR, Opler LA. The positive-negative dimension in schizophrenia. Its validity and significance. Psychiatr Develop 1987;2:79-103.
39. Pogue-Geile MF. The prognostic significance of negative symptoms in schizophrenia. Br J Psychiatry 1989;155:123-7.
40. Kay SR, Murril LM. Predicting outcome of schizophrenia: Significance of symptom profiles and outcome dimensions. Compreh Psychiatr 1990;31:91-102.
41. Fenton WS, Mc Glashan TH. Natural history of schizophrenia subtypes: I Clasical subtypes. Arch Gen Psychiatry 1991;48:969-77.
42. Davis AS, Appleby L. Diagnostic criteria in schizophrenia accentuate the positive. Schizophr Bull 1992; 18:551-7.
43. Harrow M, Silverstein M, Marengo J. Disordered thinking. Does it identify nuclear schizophrenia? Arch Gen Psychiatry 1983;40:765-71.
44. Marengo JT, Harrow M. Schizophrenic thought disorder at follow up. Arch Gen Psychiatry 1987;44:651-9.
45. Arnold OH. Schizophrenic thought disorder: comparision between units of symptoms and axial syndrome. Psychopathology 1985;18:230-6.
46. Kay SR, Singh MM. The positive-negative distinction in drug-Free schizophrenic patients. Stability, response to neuroleptics and prognostic significance. Arch Gen Psychiatry 1989;46:711-8.
47. Kay SR. Positive and negative Syndromes in Schizophrenia. Assessment and Research. Clinical and experimental Psychiatry Monograph No 5. New York: Brunner Mazel, 1991.
48. Harrow M, Silverstein M, Marengo J. Disordered thinking. Does it identify nuclear schizophrenia? Arch Gen Psychiatry 1983;40:765-71.
49. Harrow M, Marengo J. Schizophrenic thought disorder at follow up: Its persistence and prognostic significance. Schizophr Bull 1986;12:373-93.
50. Conde López VJM. Las Esquizofrenias: Una aproximación Semiológica. Real Academia de Medicina y Cirugía de Valladolid. Server-Cuesta 1984.
51. Mc Glashan. The Chestnut Lodge follow up study. I Follow up methodology and study sample. Arch Gen Psychiatry 1984;41:573-85.
52. Mc Glashan. The Chestnut Lodge follow up study. II Long term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry 1984;41:586-601.
53. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia. II Relationships between predictor and outcome variables: A report from the WHO international pilot study of schizophrenia. Arch Gen Psychiatry 1974;31:37-42.
54. Jonhson H, Nyman F. Prediction of outcome in schizophrenia. Acta Psychiat Scand 1984;69:274-91.
55. Mc Glashan TH, Fenton WS. The positive-negative distinction in schizophrenia. Review of natural history validators. Arch Gen Psychiatry 1992;49:63-72.
56. Peralta V, Cuesta MJ. Síntomas negativos en la esquizofrenia: Modelos clínicos, delimitación conceptual, significación clínica, fisiopatología y tratamiento. En Gutiérrez M, Ezcurra J, Pichot J, editores. Esquizofrenia entre la sociogénesis y el condicionamiento biológico II. Tomo I. Barcelona: Ediciones en Neurociencias, 1995:39.
57. Leal Cercos C, Iglesias Rodríguez F, Montera Piñar I. Evolución y pronóstico de la esquizofrenia en pacientes ingresados en una unidad psiquiátrica de Hospital General. An Psiquiatría 1984;1(1):50-5.
58. Goodwin FK, Redfield Jamison K. Manic depresive illnes. New York: Oxford University Press, 1990.